Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.67 |
| ▸ | LPL | P06858 | 10/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26048046 | 0.97 | LIPG (0.61) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL21065677 | 0.91 | LIPG (0.73) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL28718456 | 0.91 | LIPG (0.73) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL21065673 | 0.86 | LIPG (0.70) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL30462985 | 0.86 | LIPG (0.70) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL22722773 | 0.85 | LIPG (0.55) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL24449199 | 0.83 | LIPG (0.61) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL15282754 | 0.83 | LIPG (0.57) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL20088883 | 0.83 | LIPG (0.76) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL17726029 | 0.83 | LIPG (0.76) | LIPGLPLPDGFRBKDRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099897-A1 | ARYLAMINE COMPOUND AND ELECTRONIC APPARATUS USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099897-A1 | ARYLAMINE COMPOUND AND ELECTRONIC APPARATUS USING SAME | SLC7A5, SLC43A1, SLCO4C1 | LIPG 1569/4885LPL 1122/4885PDGFRB 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.